EWTX - Company ID 0001710072
The table below shows Edgewise Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$42.54M | -$37.87M | -$28.60M | -$22.83M | -$12.57M | -$6.06M |
| Capital expenditure | $260.00K | $44.00K | $297.00K | $4.37M | $369.00K | $62.00K |
| Investing cash flow | $2.43M | $43.90M | -$268.31M | $49.04M | $31.39M | -$64.77M |
| Dividends paid | - | - | - |
Edgewise Therapeutics, Inc. reported operating cash flow of -$143.82M for fiscal year 2025. That is down 31.9% from -$109.03M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$14.63M (FY 2020) to -$143.82M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $12.17M | $2.22M | $241.07M | $21.00K | $73.00K | $186.95M |